TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03319095

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravaginal Electrical Nerve Stimulation
Description: The Intervention group will receive Intravaginal Electrical Nerve Stimulation using Quark® Dualpex equipment, once per week during 8 weeks. The selected current will be biphasic, and the stimulation parameters will be: 50 Hz frequency, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds, relaxation time (Toff) of 10 seconds, intensity of current defined according to the sensitivity (tolerance) of the patient, and total stimulation time of 20 minutes once a week delivered by an experienced Physiotherapist. In the last 10 minutes of each electrical nerve stimulation session women will be requested to perform voluntary PFM contractions along with the contractions induced by the electrical stimulation. Women will not be instructed to perform any aditional exercise or therapy at home.
Study: NCT02531594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT
Description: The Social Worker will provide caregivers with the brief (10-15 minute) Advise, Assess, Assist intervention based on the Clinical Practice Guidelines, and tailored on levels of motivation to quit and tobacco dependence. Patients in this group will receive Nicotine Replacement Therapy vouchers, immediate connection to cessation resources, and intervention materials.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: HHC
Description: The Social Worker will provide caregivers with the brief (10-15 minute) Lets Go! 5-2-1-0 intervention which is a child obesity prevention program. Patients in this group will receive motivational interviewing in regards to helping children and families eat healthy and be active. This group will receive water bottle vouchers, immediate connection to 5-2-1-0 resources, and intervention materials.
Study: NCT01042535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adenovirus-p53 transduced dendritic cell (DC) vaccine
Description: Given intradermally (ID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-methyl-d-tryptophan
Description: Given orally (PO)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study: NCT03919448

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Single-dose infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Single-dose infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Single-dose infusion
Study: NCT02994628

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Water only without carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mini banana
Description: Ingest mini banana containing higher phenolics and carbohydrate concentration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cavendish banana
Description: Ingest Cavendish banana (common banana)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6% sugar beverage
Description: Ingest 6% sugar beverage containing same glucose and fructose profile as banana
Study: NCT01524172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Based Psychotherapy Group
Description: YBPG promotes self-regulation (attention span and physical and verbal expression/outbursts); self-soothing (breathing and movement techniques that physiologically calm when the child encounters stress or reminders of trauma); competency (successful social interaction, appropriate expression of needs and feelings, healthy coping with stress or crisis); self-awareness (of thoughts and feelings by first increasing awareness of the body and its sensations through yoga); self-esteem (positive self-regard, increase accomplishments and awareness that all individuals have different abilities); and safety and personal boundaries (establishing personal boundaries and respecting others' personal boundaries, differentiate safe and unsafe behaviors and situations).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Mental Health Treatment
Description: Trauma and evidence informed therapy
Study: NCT03813745

Intervention type: OTHER
Intervention: early denudation
Description: COCs will be denudated in 30 min after oocyte retrieval

Intervention type: OTHER
Intervention: late denudation
Description: COCs will be denudated 2 hr after oocyte retrieval
Study: NCT00696462

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: forced-air warming
Description: forced-air warming device
Study: NCT02775760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular endurance
Description: Physical exercise at the Boston University Fitness and Recreation Center

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength, balance, and flexibility
Description: Physical exercise at the Boston University Fitness and Recreation Center
Study: NCT05388162

Intervention type: DEVICE
Group type: OTHER
Intervention: Mobile colposcope
Description: It is a comparison trial - Comparing a standard colposcpoe with a smart-phone based colpsocpe.
Study: NCT03785886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking group
Description: Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β-blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chinese square dancing group
Description: Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study.~Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
Study: NCT00645424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks
Study: NCT02450877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine

Intervention type: OTHER
Group type: OTHER
Intervention: Control Arm
Study: NCT04999410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Interventions will contrast alternative training protocols

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training
Description: Interventions will contrast alternative training protocols

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training
Description: Interventions will contrast alternative training protocols

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training
Description: Interventions will contrast alternative training protocols
Study: NCT02346669

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastroscopy
Description: as detailed in arm description

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: gastroscopy
Description: as detailed in arm description

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastroscopy
Description: as detailed in arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: as detailed in arm description
Study: NCT03279718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal Treatment
Description: Scaling and root planing
Study: NCT01194154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
Study: NCT03219645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Diterpene Lactone Meglumine Injection
Description: The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
Study: NCT04617353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NO-based treatment of sterno-mediastinitis
Description: Preparation of a postoperative wound in case of infectious complications. A mandatory sampling material for culture and antibiotic sensitivity is collected before and after the air plasma flow treatment.~Direct effect of the air-plasma flow on the entire wound surface in sterilization mode with an exposure of 2-3 minutes for each surgical wound, until the level of bacterial contamination decreases to 10-5 and below.~The technique of using air-plasma flow when closing a wound after preventing infectious complications in it.~In the postoperative period, daily air-plasma flow treatment in sterilization mode along the suture line for 3 minutes. Penetrating drainage NO supply in the biological stimulation mode daily for 10 days, with an exposure of 1-2 minutes up to 10 days, with a volume of up to 2 liters per minute.~Collecting wound culture from the drainage containers on 1-3-7-12 days to detect pathogens and the bacterial number.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Treatment of sterno-mediastinitis
Description: patients who were treated for sterno-mediastinitis according to clinical guidelines, the main method of which is a permanent irrigation and aspiration flow drainage method, as well as a Vacuum Assisted Closure (VAC) system of dressings for vacuum drainage
Study: NCT04267744

Intervention type: OTHER
Group type: OTHER
Intervention: Myia Health® remote patient monitoring unblinded treatment arm
Description: After consenting to the study, the Myia in-home suite of devices will be provided to all recruited patients. The data flowing from the Myia platform will be available to clinicians and patients for the duration of the pilot and utilized to complete study activities.~Device: Myia Health platform and in-home suite of devices®:~Emfit Ballistocardiograph® Withings Connected Scale® VitalScout (VivaLink) ECG Accelerometer® Omron Blood Pressure Monitor® (Sphygmomanometer) Cradlepoint - Hotspot / Adaptor® (LTE Connection) Samsung Galaxy Tab A 8.0® (User Interface)
Study: NCT02004587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemigliptin
Description: Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Description: Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Description: Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.
Study: NCT02975440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 11 single oral doses of 600 mg Rifampicin resulting in a total dose of 6600 mg Rifampicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 single oral doses of 1 mg Midazolam resulting in a total dose of 2 mg Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1002670_Vilaprisan
Description: 2 single oral doses of 4 mg Vilaprisan resulting in a total dose of 8 mg Vilaprisan
Study: NCT00724724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide Soft Capsules
Description: Butylphthalide Soft Capsules: 2 tablets Bid for 1 year Aspirin: 100mg for 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100mg Qd for 1 year
Study: NCT03397927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthosis
Study: NCT02792010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip cartilage MRI
Description: Hip cartilage MRI
Study: NCT04486963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanhuangjingshimingwan
Description: Sanhuangjingshimingwan,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sanhuangjingshimingwan Placebo
Description: Sanhuangjingshimingwan Placebo,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
Study: NCT00625521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASF 1096 0.5 % cream applied twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream vehicle for ASF 1096 cream applied twice daily
Study: NCT01928121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care provided by AF expert program
Study: NCT00929734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10mg tablets, once daily in three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet, once daily in three months
Study: NCT01157182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/Norethindrone acetate
Description: 1/0.5 mg Tablets
Study: NCT04141852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of VasQ device
Description: The VasQ external support device (Laminate Medical Technologies, Israel) is a novel Nitinol implant, externally surrounding and supporting the vein and hugging the artery near the junction site, without being in contact with the blood flow.
Study: NCT04538092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery Protocol
Description: The investigators have developed an Enhanced Recovery After Surgery protocol for complex spine surgery at UNC. This study will help elucidate the effects of multiple interventions tailored to help patients recover from complex surgery.
Study: NCT01157182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Activella®
Description: 1/0.5 mg Tablets
Study: NCT03768843

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Harms technique
Description: Atlantoaxial fusion
Study: NCT02669862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Solution 40

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Solution 45

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Solution
Study: NCT05164406

Intervention type: PROCEDURE
Intervention: Blood salvage therapy
Description: In the blood salvage group, blood is systematically given back when the minimal amount of blood loss required for reprocessing is met
Study: NCT00444509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: GW685698X will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: GW685698X will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X containing magnesium stearate
Description: GW685698X containing magnesium stearate will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X containing magnesium stearate
Description: GW685698X containing magnesium stearate will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
Study: NCT01124201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization , strengthening and stretching
Description: Interventions were conducted over 6 weeks, twice per week, lasting 30 minutes each. Sessions were supervised by the investigator, and participants were instructed to report any adverse event. Groups were instructed not to participate in any other physical program during the study. Forty-five patients were randomized into three groups namely: Segmental stabilization group (ES)(transversus abdominis and lumbar multifidus), superficial strengthening group (FS)(rectus abdominis, oblique abdominal muscles and erector spinae muscles) and stretching group (AL) (erector spinae, posterior connective tissues and ischiotibials muscles). Patients were evaluated for pain , functional disability,and ability to contract the TrA before and after the treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization , strengthening and stretching
Description: Interventions were conducted over 6 weeks, twice per week, lasting 30 minutes each. Sessions were supervised by the investigator, and participants were instructed to report any adverse event. Groups were instructed not to participate in any other physical program during the study. Forty-five patients were randomized into three groups namely: Segmental stabilization group (ES)(transversus abdominis and lumbar multifidus), superficial strengthening group (FS)(rectus abdominis, oblique abdominal muscles and erector spinae muscles) and stretching group (AL) (erector spinae, posterior connective tissues and ischiotibials muscles). Patients were evaluated for pain , functional disability,and ability to contract the TrA before and after the treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization , strengthening and stretching
Description: Interventions were conducted over 6 weeks, twice per week, lasting 30 minutes each. Sessions were supervised by the investigator, and participants were instructed to report any adverse event. Groups were instructed not to participate in any other physical program during the study. Forty-five patients were randomized into three groups namely: Segmental stabilization group (ES)(transversus abdominis and lumbar multifidus), superficial strengthening group (FS)(rectus abdominis, oblique abdominal muscles and erector spinae muscles) and stretching group (AL) (erector spinae, posterior connective tissues and ischiotibials muscles). Patients were evaluated for pain , functional disability,and ability to contract the TrA before and after the treatment.
Study: NCT03534063

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2D6-guided opioid therapy
Description: Using a standardized consult note, recommendations were made to avoid tramadol, hydrocodone, codeine, and oxycodone in PMs, IMs, and UMs and to use an alternative opioid (e.g. morphine, hydromorphone) or non-opioid (e.g. NSAID). Consideration of tramadol as the first-line opioid will be recommended for NMs.
Study: NCT01483898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixmyelocel-T
Description: On Day 14, 20 intramuscular injections of ixmyelocel-T on pre-identified index leg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On Day 14, 20 intramuscular injections of vehicle control on pre-identified index leg.
Study: NCT00492856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given orally
Study: NCT04516564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK119
Description: Single dose of AK119 is administered via intravenous infusion to healthy subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo is administered via intravenous infusion to healthy subjects
Study: NCT03326648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Heavy load strength training performed twice a week for 10 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.
Study: NCT02346669

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: as detailed in arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: as detailed in arm description
Study: NCT00492856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Description: Given orally
Study: NCT03766724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin→Evogliptin+Empagliflozin→Empagliflozin
Description: Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD, Empagliflozin : Empagliflozin 25mg QD
Study: NCT02211014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Study: NCT04158817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Labeled PSMA
Description: All participants in the study will be injected with 68Ga-THP-PSMA at a dose of 2.11 MBq/kg in a single dose injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-labeled PSMA
Description: Patient will be injected with microdose (\<100 ug) of THP-PSMA